While Pfizer called the bid “reckless”, Metsera disagrees, stating that it will review the “superior proposal”.

From a more company-specific point of view, Pfizer has also agreed to buy Metsera. This will help the company deal with upcoming patent cliffs, in which older drugs lose their patent protections. The acquisition was necessitated by the fact that Pfizer's own drug pipeline was looking a little weak.